Summary | In a big boost for Merck, the drug maker late
yesterday disclosed positive news about a long-awaited clinical
trial that was designed to test the safety of its best-selling
Januvia diabetes tablet. Known as Tecos, the trial showed that
Januvia met the primary goal of showing comparable
cardiovascular safety versus a placebo. Moreover, the drug did ...
yesterday disclosed positive news about a long-awaited clinical
trial that was designed to test the safety of its best-selling
Januvia diabetes tablet. Known as Tecos, the trial showed that
Januvia met the primary goal of showing comparable
cardiovascular safety versus a placebo. Moreover, the drug did ...
blogs.wsj.com | 28 April 2015